The efficacy of miRNA122, a novel therapeutic target, for predicting the progression of hepatocellular carcinoma （HCC）

作     者：Lifeng Wang Zheng Zhang Fu-Sheng Wang 

作者机构：Research Center for Biological TherapyThe Institute of Translational HepatologyBeijing 302 HospitalBeijingChina 

出 版 物：《Cellular & Molecular Immunology》 (中国免疫学杂志（英文版）)

年 卷 期：2012年第9卷第2期

页      面：103-104页

核心收录：

学科分类：0710[理学-生物学] 081702[工学-化学工艺] 07[理学] 08[工学] 0817[工学-化学工程与技术] 09[农学] 071007[理学-遗传学] 0901[农学-作物学] 0836[工学-生物工程] 090102[农学-作物遗传育种] 

主　　题：miRNA122 hepatocellular carcinoma 

摘      要：Hepatocellular carcinoma （HCC） is the fifth most prevalent malignancy worldwide, and it accounts for 85-90% ot all primary liver cancers. Owing to the limited therapeutic options available, the 5-year survival rate remains relatively low for patients with HCC. The development of HCC is a multistage process1 that involves changes in the expression of multiple oncogenes, tumor suppressor genes and microRNAs that are involved in the cell cycle, as well as in cell growth, apoptosis, migration and tumor metastasis.2,3 Finding an accurate biomarker that can predict HCC progression is import- ant for clinicians to be able to determine the optimal therapeutic strategy.